Karyopharm Therapeutics KPTI 深 滬
交易中 10-10 11:35:35 美东时间
5.585
-0.235
-4.04%
華盛通- 最 高5.95
- 今 開5.91
- 成交量 5.17万股
- 最 低 5.50
- 昨 收 5.82
- 總市值 4842.92万
- 52周最高 16.95
- 市盈率 靜 --
- 換手率 0.60%
- 52周最低 3.51
- 委 比 -88.79%
- 總股本 867.13万
- 歷史最高 735.075
- 量 比 0.23
- 振 幅 7.73%
- 歷史最低 5.50
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
今天 11:36
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $21
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $25 to $21.
10-09 20:08
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
10-09 01:31
Karyopharm Secures $100M Financing for Clinical Trials
An update from Karyopharm Therapeutics ( ($KPTI) ) is now available. On October...
10-08 19:29
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
KOMET-001 trial demonstrates significant clinical benefit of ziftomenib in relapsed/refractory NPM1-m AML, meeting primary endpoint with 22% complete remission rate. The drug shows consistent activity across subgroups, favorable safety profile, and no significant QTc prolongation or myelosuppression. FDA Priority Review with PDUFA date set for November 30, 2025. Currently, no approved therapy targets NPM1-m AML.
09-25 21:18
Karyopharm Completes Enrollment In Phase 3 Trial Testing New Combo Therapy For Myelofibrosis Patients
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating
09-10 19:02
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that th...
09-03 04:05
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $25
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $42 to $25.
08-12 19:41
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140M-$155M vs $145.358M Est
2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for full year 2025:Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net
08-11 19:34
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
